Malafin Tablets -2's

Malafin's primary indication is within public health strategies aimed at high-risk populations:

• Intermittent Preventive Treatment in Pregnancy (IPTp): The definitive use for this formulation. It is administered to pregnant women at scheduled antenatal visits to clear existing parasites and prevent malaria in the placenta, thereby reducing maternal anemia and improving infant birth weight.
• Directly Observed Treatment (DOT): IPTp doses are typically given under DOT to ensure the full, single dose is taken immediately and correctly.
• Uncomplicated Malaria Treatment: Used for curing malaria infection caused by Plasmodium species in regions where the parasites remain susceptible to this combination.

Dosage and Administration

The entire dose must be taken at once, as a single administration:

• Standard Dose (IPTp/Treatment): Two (2) tablets are taken together.
• Administration: Swallow the tablets whole with food or a glass of milk. Taking with food significantly enhances drug absorption and reduces the incidence of gastrointestinal side effects.

Severe Warnings and Contraindications

Use of Malafin requires strict adherence to medical guidance due to potential severe risks:

• Sulfa Allergy: Contradicted in patients with known hypersensitivity to sulfonamide (sulfa) drugs or Pyrimethamine.
• G6PD Deficiency: Use with extreme caution. This drug can precipitate severe hemolytic anemia in individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
• Folate Deficiency: Should not be used in individuals with pre-existing megaloblastic anemia due to folate deficiency.

Side Effects and Interactions

Common Side Effects: Nausea, vomiting, abdominal pain, and mild skin reactions.

Drug Interactions: Malafin should not be administered concurrently with other folate antagonists, such as Trimethoprim/Sulfamethoxazole (Cotrimoxazole) or Methotrexate, as this significantly increases the risk of hematological toxicity.

Malafin Summary Table (2-Tablet Dose)